Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Binding Proteins | 7 | 2020 | 482 | 1.020 |
Why?
|
| Transcription Factors | 7 | 2020 | 511 | 1.010 |
Why?
|
| Prostatic Neoplasms | 5 | 2019 | 270 | 0.920 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 7 | 2020 | 43 | 0.900 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2020 | 443 | 0.780 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2013 | 13 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 377 | 0.420 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2019 | 10 | 0.380 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 25 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 4 | 2020 | 332 | 0.320 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 133 | 0.310 |
Why?
|
| Cell Proliferation | 6 | 2020 | 770 | 0.270 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2012 | 27 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2013 | 18 | 0.210 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 194 | 0.200 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2012 | 50 | 0.190 |
Why?
|
| Luciferases | 2 | 2012 | 49 | 0.190 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 86 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 323 | 0.180 |
Why?
|
| Apoptosis | 3 | 2012 | 737 | 0.180 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2020 | 20 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2012 | 503 | 0.160 |
Why?
|
| Smad Proteins | 1 | 2019 | 18 | 0.160 |
Why?
|
| RNA, Messenger | 2 | 2012 | 645 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 60 | 0.160 |
Why?
|
| Protein Binding | 4 | 2016 | 631 | 0.150 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 1259 | 0.140 |
Why?
|
| Phosphoproteins | 1 | 2016 | 115 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 114 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 160 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 98 | 0.120 |
Why?
|
| Humans | 12 | 2020 | 26856 | 0.120 |
Why?
|
| Base Sequence | 2 | 2012 | 573 | 0.120 |
Why?
|
| Cell Movement | 2 | 2013 | 353 | 0.110 |
Why?
|
| HCT116 Cells | 3 | 2020 | 53 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1036 | 0.110 |
Why?
|
| 14-3-3 Proteins | 1 | 2013 | 9 | 0.110 |
Why?
|
| Exoribonucleases | 1 | 2013 | 20 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 129 | 0.100 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2012 | 6 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 310 | 0.100 |
Why?
|
| Male | 5 | 2019 | 12866 | 0.100 |
Why?
|
| HEK293 Cells | 3 | 2019 | 173 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 457 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 139 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 117 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1474 | 0.090 |
Why?
|
| Prognosis | 1 | 2012 | 758 | 0.090 |
Why?
|
| Microdissection | 1 | 2009 | 14 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2009 | 23 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 67 | 0.080 |
Why?
|
| Prostate | 1 | 2009 | 51 | 0.080 |
Why?
|
| Lasers | 1 | 2009 | 67 | 0.080 |
Why?
|
| Androgens | 1 | 2009 | 47 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 51 | 0.080 |
Why?
|
| Cell Line | 3 | 2019 | 671 | 0.080 |
Why?
|
| Transfection | 1 | 2009 | 312 | 0.080 |
Why?
|
| Binding Sites | 1 | 2009 | 338 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 487 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2020 | 16 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 441 | 0.070 |
Why?
|
| Mice | 2 | 2019 | 4402 | 0.060 |
Why?
|
| Animals | 3 | 2019 | 9954 | 0.060 |
Why?
|
| Mutation | 2 | 2020 | 820 | 0.050 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 8 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 34 | 0.040 |
Why?
|
| Gene Expression | 2 | 2012 | 405 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2020 | 129 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 399 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 13 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 79 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 57 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 277 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 437 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 450 | 0.040 |
Why?
|
| Neoplasms | 2 | 2019 | 756 | 0.040 |
Why?
|
| Female | 2 | 2012 | 14462 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 781 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1564 | 0.030 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2016 | 10 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 135 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 1339 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 180 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 196 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 26 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2012 | 14 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2012 | 19 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 22 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 144 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 143 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 559 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2012 | 74 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 131 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 155 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 100 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 282 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 674 | 0.020 |
Why?
|